Stock Analiz

Krystal Biotech, Inc. (KRYS) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Net income in fiscal 2025 was $205M, a net margin of 52.6%; the highest of the period.

Over the twelve months to September 30, 2026, revenue was $470M and net income $225M.

Free cash flow was $189M in fiscal 2025 and positive in 2 of the 10 years shown.

The diluted share count rose 3313% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2021: $020212022: $020222023: $51M20232024: $291M20242025: $389M2025$389M
Net income
2016: -$1M162017: -$8M172018: -$11M182019: -$19M192020: -$32M202021: -$70M212022: -$140M222023: $11M232024: $89M242025: $205M25$205M
Free cash flow
2016: -$1M162017: -$4M172018: -$12M182019: -$25M192020: -$41M202021: -$116M212022: -$154M222023: -$101M232024: $119M242025: $189M25$189M
EPS (diluted)
2016: $-1.31162017: $-1.48172018: $-0.97182019: $-1.20192020: $-1.71202021: $-3.13212022: $-5.49222023: $0.39232024: $3.00242025: $6.8425$6.84

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$470M$389M$291M$51M$0$0—————
Gross profit———————————
Operating income$228M$161M$66M-$110M-$145M-$68M-$33M-$22M-$12M-$5M-$1M
Net income$225M$205M$89M$11M-$140M-$70M-$32M-$19M-$11M-$8M-$1M
EPS (diluted)$7.37$6.84$3.00$0.39$-5.49$-3.13$-1.71$-1.20$-0.97$-1.48$-1.31
R&D$60M$58M$54M$46M$42M$28M$18M$16M$8M$3M$741000
Revenue growth—+33.9%+473.0%————————

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow$324M$201M$123M-$89M-$101M-$48M-$26M-$19M-$9M-$4M-$1M
Capital spending-$14M-$12M-$4M-$12M-$53M-$68M-$15M-$6M-$2M-$210000-$15000
Free cash flow$310M$189M$119M-$101M-$154M-$116M-$41M-$25M-$12M-$4M-$1M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks———————————
Stock-based pay$55M$55M$49M$40M$33M$15M$3M$1M$792000$246000$33000

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$828M$598M$532M$379M$438M$271M$194M$112M$50M$2M
Debt—$9M$7M$8M$9M$8M$4M$3M—$0$2M
Equity—$1.2B$946M$779M$522M$594M$292M$203M$113M$49M$289000
Total assets—$1.3B$1.1B$818M$558M$626M$311M$209M$116M$50M$2M
Shares (diluted)31M30M30M28M25M22M19M16M11M5M1M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin———————————
Operating margin48.4%41.4%22.6%-216.2%———————
Net margin47.9%52.6%30.7%21.6%———————
FCF margin66.0%48.5%41.0%-198.4%———————
ROIC—10.4%6.5%-11.8%-27.3%-11.3%-8.8%-8.5%-8.3%-7.6%-43.2%
ROE—16.8%9.4%1.4%-26.8%-11.7%-11.0%-9.4%-9.6%-16.0%-397.9%

Frequently asked questions

What is Krystal Biotech’s annual revenue?

$389M in fiscal 2025 and $470M over the twelve months to September 30, 2026.

How much profit does Krystal Biotech make?

Net income was $205M in fiscal 2025 (net margin 52.6%).

Is Krystal Biotech’s revenue growing?

Yes: revenue rose 33.9% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.